XML 49 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Restatement of Financial Statements (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Net Sales $ 2,051,734 $ 1,384,429 $ 3,583,614 $ 4,252,704
Cost of Sales 535,572 388,202 1,068,174 1,268,320
Gross Profit 1,516,162 996,227 2,515,440 2,984,384
Operating expenses        
Compensation and related expenses 529,361 361,829 1,131,805 1,077,340
Professional fees 99,964 82,608 321,548 277,282
Marketing expenses 882,845 554,536 1,182,715 1,713,337
General and administrative expenses 277,559 204,958 753,402 382,857
Total operating expenses 1,789,729 1,203,931 3,389,470 3,450,816
Operating Income (Loss) (273,567) (207,704) (874,030) (466,432)
Interest (expense) (1,111) (9,992) (650,718) (15,805)
Net Income (Loss) Before Taxes   (217,696)   (482,237)
Deferred income tax benefit    
Net Income (Loss)   (217,696)   (482,237)
Net (loss) income attributable to noncontrolling interests 27,172 8,955 (41,752) 6,439
Net (loss) attributable to Immudyne, Inc. $ (679,063) $ (226,651) $ (986,379) $ (488,676)
Basic and diluted (loss) per share attributable to Immudyne, Inc.   $ (0.01)   $ (0.02)
Average number of common shares outstanding        
Basic 44,160,477 34,427,087 40,888,131 31,917,873
Diluted 44,160,477 34,427,087 40,888,131 31,917,873
As Reported [Member]        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Net Sales   $ 1,384,429   $ 4,252,704
Cost of Sales   942,738   2,981,657
Gross Profit   441,691   1,271,047
Operating expenses        
Compensation and related expenses   361,829   1,077,340
Professional fees   82,608   277,282
Marketing expenses    
General and administrative expenses   204,958   382,857
Total operating expenses   649,395   1,737,479
Operating Income (Loss)   (207,704)   (466,432)
Interest (expense)   (9,992)   (15,805)
Net Income (Loss) Before Taxes   (217,696)   (482,237)
Deferred income tax benefit    
Net Income (Loss)   (217,696)   (482,237)
Net (loss) income attributable to noncontrolling interests   8,955   6,439
Net (loss) attributable to Immudyne, Inc.   $ (226,651)   $ (488,676)
Basic and diluted (loss) per share attributable to Immudyne, Inc.   $ (0.01)   $ (0.02)
Average number of common shares outstanding        
Basic   34,427,087   31,917,873
Diluted   34,427,087   31,917,873
Adjustment [Member]        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Net Sales    
Cost of Sales   (554,536)   (1,713,337)
Gross Profit    
Operating expenses        
Compensation and related expenses    
Professional fees    
Marketing expenses   554,536   1,713,337
General and administrative expenses    
Total operating expenses    
Operating Income (Loss)    
Interest (expense)    
Net Income (Loss) Before Taxes    
Deferred income tax benefit    
Net Income (Loss)    
Net (loss) income attributable to noncontrolling interests    
Net (loss) attributable to Immudyne, Inc.    
Basic and diluted (loss) per share attributable to Immudyne, Inc.    
Average number of common shares outstanding        
Basic    
Diluted